MADISON, Wis., Oct. 22, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced late-breaking data from the pivotal ...

Next-generation Cologuard exhibited improved colorectal cancer specificity and sensitivity compared with results of the FDA registrational trial that led to approval of the noninvasive screening test, ...

Women living with and without HIV, age 30-65 years, were recruited in South Africa. Self-collected vaginal samples and clinician-collected cervical samples were tested with Xpert HPV, an assay that ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. “More than three out of four Americans who die from ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of Natera’s ...

Conclusions The K-D has fair test-retest reliability. The combination of sensitivity and specificity with any increase in time is better than other currently used objective measures of concussion.

WASHINGTON -- A blood-based test for the early detection of colorectal cancer (CRC) met its prespecified sensitivity and specificity endpoints, according to results from the PREEMPT CRC study. Using ...

Note: specificity including non-advanced findings includes colonoscopy results that were negative for cancer or advanced precancer upon histopathological review; specificity including no findings ...

Among patients with asthma-like symptoms in primary care, testing using home spirometry may be useful for the diagnosis of ...

A look at Exact Sciences Corporation’s acquisition by Abbott: review EXAS revenue growth, margins, and CRC/MRD screening ...